C. diff is suspected of causing almost all intestinal infections following therapy with antibiotics. Older people are at greater risk of getting C. diff because they are more likely to be ...

Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...

Hypoxia-inducible factor (HIF) signaling protects the intestinal mucosa from injury induced by Clostridium difficile toxins, according to the results of a study published in Gastroenterology.

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Clostridium difficile (C.diff) intestinal infections are included because hospital staff can prevent the C. diff bacterium from being transmitted to patients. The bacterium causes diarrhea and ...

shows promise in mitigating Clostridioides difficile (C. difficile) infection, particularly those resistant to antibiotics. A pilot study conducted in a mouse model suggests that tagatose could ...

"We discovered that mice that don't produce this protein are more protected against intestinal infections ... protect the gut from infections such as those caused by C. difficile.

A Novel First-in-Class Microbiome-Restoration Therapy for the Prevention of Recurrence of C. diff Infection Ferring's novel first-in-class REBYOTA is indicated for the prevention of recurrence of ...